MA CRO/CMO & DD: Drug Discovery & Outsourcing of Essential Functions

Thursday, September 27 2012
8:00 am – 10:00 am

Location: MassBio, 300 Technology Square, 8th Floor, Cambridge, MA

The goal of this meeting will be to discuss the benefits and possible harm of outsourcing discovery functions from early Discovery Chemistry, ADMET, and in vitro and in vivo Pharmacology.

The overall topics will focus on answering questions such as:

  • Are the goals of small pharma different from those of multinationals with respect to what they elect to outsource and where in the world they select vendors?
  • Has outsourcing of discovery functions accelerated hit-to-IND timelines?
  • Is there a long term negative impact on the US from outsourcing Discovery outside the US?

Speakers include:

Moderator:

  • Dr. Peter Meltzer, President & CEO Organix, Inc.

Panelists:

  • Dr. Bharat Lagu, Associate Director, External Drug Discovery, Novartis Institute for Biomedical Research
  • Dr. Nick Terrett, Chief Scientific Officer, Ensemble Therapeutics Corp
  • Dr. Curtis Keith, Chief Scientific Officer, Harvard University, Technology Development Accelerator Fund
  • Carolyn Green, President & Director, Atreaon, Inc.
  • Dr. John Petersen, Vice President, Research and Development, SynDevRx

Questions provided to the panel include:

  • Are the goals of small pharma different from those of multinationals with respect to what they elect to outsource and where in the world they select vendors?
    • Are there short vs. long term considerations when selecting countries to outsource to?
      • Is the future market of products of overriding importance to large pharma?
      • Are efficiency and timeliness the major consideration for emerging pharma?
      • Does security of IP govern the selection of outsourcing?       
      • Are these questions answered differently based upon scientific vs. cost (business) considerations?
  • Has outsourcing of discovery functions accelerated hit-to-IND timelines?
    • Do large pharma and small pharma see similar timeline advantages?
      • Is it too early (outsourcing is relatively new) to reach a definitive answer to this question?
      • What are the measures of outsourcing success for large vs. small pharma?
    • Does quality of outsourcing affect large and emerging pharma differently?
      • Large pharma’s goal is to take discovery from conception to the market place.
      • Emerging and small pharma’s goal is to take discovery to a point of licensing.
  • Is there a long term negative impact on the US from outsourcing Discovery outside the US?
    • Is there a potential loss of IP depending upon legal systems and countries?
    • Does this drive an increasing shift of technological know how away from the US?
    • Does this drive scientists educated in the US to move to, and facilitate rapid advances in competing economies?
    • Does the US lose the best and brightest of US trained scientists thus impacting continued scientific advance in the US?

 

Speaker Bios:

Dr. Bharat Lagu, Associate Director, External Drug Discovery, Novartis Institute for Biomedical Research.

  • Past Experience: Team Leader, Johnson & Johnson; Group Leader, Synaptic Pharmaceutical Group.
  • PhD – Clemson University

Dr. Nick Terrett, Chief Scientific Officer, Ensemble Therapeutics Corp.

  • Past Experience: Senior Director & Head of Chemical Sciences, Pfizer, MA; Director of Lead Discovery Technologies, Pfizer, UK.

Dr. Curtis Keith, Chief Scientific Officer, Harvard University, Technology Development Accelerator Fund.

  • Past Experience: Senior VP Research, CombinatorRx.
  • PhD – Harvard University
  • BSc – McGill University

Carolyn Green, President and Director, Atreaon, Inc.

  • Past Experience: President & COO, Logical Therapeutics Inc.; Director, Enterprise Development, University of Pittsburgh; Leadership Pittsburgh, Board of Directors; Director, Office of Enterprise Development, University of Pittsburgh.
  • Executive Education, Harvard Business School
  • BS – University of Pittsburgh

Dr. John Petersen, Vice President, Research and Development, SynDevRx.

  • Past Experience: V.P. Transport Pharmaceuticals, Senior Director; Manufacturing, Genzyme; Director Manufacturing, GelTex.
  • PhD – University of California, Berkeley
  • BS – Massachusetts Institute of Technology

Share MassBio

 

 

MassBio Golf Classic

BioProcess

EvaluatePharma